Biological Evaluation and Docking Studies of Synthetic Oleanane-type Triterpenoids.

Clicks: 319
ID: 3609
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #103 of 475 articles by views in ACS omega

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 475 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Saponins are potential wide-spectrum antitumor drugs, and copper(I) catalyzed azide-alkyne 1,3-dipolar cycloaddition is a suitable approach to synthesizing saponin-like compounds by regioselective glycosylation of the C2/C3 hydroxyl and C28 carboxylic groups of triterpene aglycones maslinic acid (MA) and oleanolic acid (OA). Biological studies on the T-84 human colon carcinoma cell line support the role of the hydroxyl groups at C2/C3, the influence of the aglycone, and the bulky nature of the substituents in C28. OA bearing a α-d-mannose moiety at C28 (compound ) focused our interest because the estimated inhibitory concentration 50 was similar to that reported for ginsenoside Rh2 against colon cancer cells and it inhibits the G-S phase transition affecting the cell viability and apoptosis. Considering that triterpenoids from natural sources have been identified as inhibitors of nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) signaling, docking studies were conducted to evaluate whether NF-κB may be a potential target. Results are consistent with the biological study and predict a similar binding mode of MA and compound to the p52 subunit from NF-κB but not for OA. The fact that the binding site is shared by the NF-κB inhibitor 6,6-dimethyl-2-(phenylimino)-6,7-dihydrobenzo[][1,3]oxathiol-4(5)-one supports the result and points to NF-κB as a potential target of both MA and compound .
Reference Key
ortegamuoz2018biologicalacs Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ortega-Muñoz, Mariano;Rodríguez-Serrano, Fernando;De Los Reyes-Berbel, Eduardo;Mut-Salud, Nuria;Hernández-Mateo, Fernando;Rodríguez-López, Andrea;Garrido, José M;López-Jaramillo, F Javier;Santoyo-González, Francisco;
Journal ACS omega
Year 2018
DOI
10.1021/acsomega.8b01034
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.